These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

39 related articles for article (PubMed ID: 12121)

  • 1. GPC diesterase activity in human endometrial secretion. (Its variations under the action of estrogens, clomiphene citrate, D-norgestrel (post-coital and low dose) and intrauterine device (IUD).).
    Nicholson R; Calamera JC
    Int J Fertil; 1976; 21(3):176-80. PubMed ID: 12121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Enzyme with diesterase activity and its human endometrial content. Variation of effect of various estrogens and clomiphene citrate].
    Nicholson R; Calamera JC; Procaccini JC
    Obstet Ginecol Lat Am; 1974; 32(7-8):320-4. PubMed ID: 4376993
    [No Abstract]   [Full Text] [Related]  

  • 3. [Action of d-norgestrel (post-coital and minidosis) on the content of the diesterase enzyme in the human endometrium].
    Nicholson R; Calamera JC; Borghi L
    Obstet Ginecol Lat Am; 1976; 34(11-12):406-9. PubMed ID: 801620
    [No Abstract]   [Full Text] [Related]  

  • 4. [Post-coital contraception].
    Serfaty D
    Contracept Fertil Sex (Paris); 1985 Jan; 13(1 Suppl):359-64. PubMed ID: 12280207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endometrial morphology during hormone replacement therapy with estradiol gel combined to levonorgestrel-releasing intrauterine device or natural progesterone.
    Suvanto-Luukkonen E; Malinen H; Sundström H; Penttinen J; Kauppila A
    Acta Obstet Gynecol Scand; 1998 Aug; 77(7):758-63. PubMed ID: 9740525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma prolactin concentrations in women treated with low dose combination type oral contraceptives and in women using a d-norgestrel-releasing intrauterine device.
    Nilsson CG; Lähteenmäki P
    Ann Clin Res; 1978 Aug; 10(4):242-5. PubMed ID: 707973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of endometrial hyperplasia with levonorgestrel releasing intrauterine devices.
    Perino A; Quartararo P; Catinella E; Genova G; Cittadini E
    Acta Eur Fertil; 1987; 18(2):137-40. PubMed ID: 3115027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sixth fertility and sterility congress--a review.
    IPPF Med Bull; 1968; 2(3):1-4 August. PubMed ID: 12254797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of a diesterase in endometrial material from normal women.
    Calamera JC; Nicholson R; Procaccini JC
    Am J Obstet Gynecol; 1974 Jun; 119(3):411-3. PubMed ID: 4827382
    [No Abstract]   [Full Text] [Related]  

  • 10. Hormonal profile in IUD users.
    Souka AR; Rahman H; Osman M; Mohei Y; Rizk M
    Contracept Deliv Syst; 1981 Oct; 2(4):303-10. PubMed ID: 12336991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Changes of the endometrium during oral hormonal contraception with ethinyl estradiol sulfonate and norethisterone acetate or d-noregestrel].
    Büttner HH; Göretzlehner G; Rudolf K
    Zentralbl Gynakol; 1976; 98(15):914-8. PubMed ID: 970000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of dysfunctional uterine bleeding: patient preferences for endometrial ablation, a levonorgestrel-releasing intrauterine device, or hysterectomy.
    Bourdrez P; Bongers MY; Mol BW
    Fertil Steril; 2004 Jul; 82(1):160-6, quiz 265. PubMed ID: 15237006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Endometrial interference of synthetic estrogens in fertility regulation.Is it necessary to interfere with the antiovulatory mechanism at the central nervous system level in order to obtain contraception?].
    Sojo Aranda QI; Rojas T; Cortés-Gallegos V
    Ginecol Obstet Mex; 1997 Oct; 65():449-51. PubMed ID: 9432479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endometrial morphology of women using a d-norgestrel-releasing intrauterine device.
    Nilsson CG; Luukkainen T; Arko H
    Fertil Steril; 1978 Apr; 29(4):397-401. PubMed ID: 648644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of intrauterine device on histology of endometrium.
    Czernobilsky B; Rotenstreich L; Mass N; Lancet M
    Obstet Gynecol; 1975 Jan; 45(1):64-6. PubMed ID: 1110821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Should endometrial hyperplasia be regarded as a reason for abnormal uterine bleeding in users of the intrauterine contraceptive device?
    Ozalp S; Kabukcuoglu S; Tanir HM
    Eur J Contracept Reprod Health Care; 2003 Mar; 8(1):17-20. PubMed ID: 12725671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Estrogens. Contraceptive therapy].
    Sojo-Aranda I; Cortés-Gallegos V
    Ginecol Obstet Mex; 1995 Jan; 63():46-9. PubMed ID: 7896159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic effects of oral contraceptives containing 30 micrograms and 50 micrograms of oestrogen.
    Nash AL; Cornish EJ; Hain R
    Med J Aust; 1979 Sep; 2(6):277-81. PubMed ID: 230411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized comparison of ovulation induction and hormone profile between the aromatase inhibitor anastrozole and clomiphene citrate in women with infertility.
    Wu HH; Wang NM; Cheng ML; Hsieh JN
    Gynecol Endocrinol; 2007 Feb; 23(2):76-81. PubMed ID: 17454156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Ultra sonography for the localization of intra-uterine contraceptive devices (i.u.d.'s) (author's transl)].
    Meyenburg M
    Geburtshilfe Frauenheilkd; 1978 Nov; 38(11):950-7. PubMed ID: 710881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 2.